

October 7, 2014

American Peptide Company and GlyTech, Inc. Announce Co-promotion Agreement

American Peptide Company, Inc. (APC) (Vista, CA) a leading peptide manufacturer, and GlyTech Inc. (Kyoto, Japan), a world-leading developer of glycosylated drugs, announced today that they have entered into a co-promotion agreement for GlyTech's glycosylation technology. As part of the agreement, APC will leverage its sales and marketing resources to enhance GlyTech's partnering efforts and GlyTech will promote APC as a partner of choice for manufacture of its glycopeptides and glycoproteins.

GlyTech's glycosylation technology permits the synthesis of peptide and proteins with pre-attached glycans (sugars), taken from a library of over 50 different glycans. It has been shown to markedly improve drug properties such as half-life, binding affinity and selectivity, and heterogeneity. GlyTech's technology was one of the finalists for the 2013 CPhI Pharma Award for Best Innovation in Process Development and has been used in multiple projects, such as glycosylated somatostatin analogue, synthetic interferon beta 1a, and glycosylated GLP-1.

"We have worked with APC on several glycosylated peptide projects, and are excited to expand our relationship to enable us to reach a broader set of potential partners for our glycosylation technology," said Mr. Hiroaki Asai, President and CEO of GlyTech.

"Offering a differentiated, proprietary technology that can dramatically improve our customers' product attributes is very important, and we are pleased to partner with Glytech in achieving this goal, thereby serving our customers with an expanded portfolio ," said Mr. Minoru Sakakibara, President and CEO of APC.

About American Peptide Company, Inc.

American Peptide Company (APC) is a leading manufacturer of peptides and peptide conjugates. The company offers comprehensive selections of pre-manufactured catalog peptides, custom synthesis, and GMP peptide active pharmaceutical ingredients (APIs). Our California based manufacturing facilities offer synthesis services under Non GMP (Sunnyvale, California) and cGMP (Vista, California) conditions. Our cGMP manufacturing is performed under strict adherence to FDA Regulations 21 CFR parts 210, 211 and ICH Guidance Q7A. Our Total Peptide Management services support clients in the drug development process from pre-clinical thru commercial stage. Our value added services include process development, scale up production, analytical/process validation, stability studies, CMC, DMF, and regulatory support. For more information, please visit <http://www.americanpeptide.com>.

About GlyTech, Inc.

GlyTech is a world leader in glycotecnology, having established the large-scale manufacturing process for highly purified and characterized human type N-glycans as well as the chemical synthesis of glycosylated compounds, especially glycopeptides and glycoproteins. GlyTech's

technologies can contribute to developing better and lower-cost biopharmaceuticals. GlyTech expects to play a significant role in developing bio-betters, biosimilars, and innovative biopharmaceutical products.

Contact:

For further questions, please visit our websites or contact the person below.

American Peptide Company
Firuz Shakoory, Senior Director, Sales
1271 Avenida Chelsea
Vista, CA 92081 USA
Phone: (760)597-8820 ext 179 (Office)
Fax: (760)597-8816
Email: firuz@americanpeptide.com
www.americanpeptide.com

GlyTech, Inc.
Katsura Torii, CBDO
Tel.: +81 75 315 9218
Fax: +81 75 315 9225
glytech-info@glytech.jp
www.glytech.jp

End of Press Release